Abstract: Provided are an anti-HER2/PD1 bispecific antibody, preparation method, and antitumor application. Specifically, a single-chain variable fragment scFv and an immunoglobulin antibody IgG are connected by means of a peptide linker to obtain a bispecific antibody; the bispecific antibody can simultaneously target the tumor cell surface molecule HER2 antigen and T lymphocyte surface molecule PD-1. The results of experimentation show that the bispecific antibody provided is capable of inhibiting the proliferation of HER2-positive tumor cells while also blockading the binding of PD-1/PD-L1, releasing the suppressive state of T cells and performing an antitumor function.

Abstract: Provided are an anti-HER2/PD1 bispecific antibody, preparation method, and antitumor application. Specifically, a single-chain variable fragment scFv and an immunoglobulin antibody IgG are connected by means of a peptide linker to obtain a bispecific antibody; the bispecific antibody can simultaneously target the tumor cell surface molecule HER2 antigen and T lymphocyte surface molecule PD-1. The results of experimentation show that the bispecific antibody provided is capable of inhibiting the proliferation of HER2-positive tumor cells while also blockading the binding of PD-1/PD-L1, releasing the suppressive state of T cells and performing an antitumor function.

Abstract: Provided is an anti-PDL1×EGFR bispecific antibody. Experimental results show that the bispecific antibody can maintain relatively well the activity of anti-EGFR and anti-PD-L1 monoclonal antibodies; in addition, same can specifically bind to the two PD-L1 and EGFR targets at the same time, and more importantly, said bispecific antibody has obvious synergy at the cellular level.